|
|
|
|
Science Sparks @ ACTREC
|
 12th October 2026 |
Vol. No. 15 ; Issue No.756 |
|
|
Publications
|
|
1. Urun Y, Sridharan K, Zgura A, Zayed A, Laguado MIZ, Yetisyigit T, Yano A, Wenzel M...., Maitre P, Maison P, Ndjembidouma BCM, Lu K, Li J, Li H, de Moura Leite L, Lalani AA, Küronya Z, Kucharz J, Koumba AB, Kopp RM, Kopecky J...etal (2026). Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey. Oncologist.
2. Varyani RA, Waghmare M, Saha P, CM Krishna, Bajaj M, Mane P, Kathale A, Mundhe V, Gaikwad P (2026). Biofluid based biochemical and clinicopathological profiling for the detection and stratification of oral potentially malignant disorders. Clinical Oral Investigation. 30(10):509.
3. Arora M, Panda R, Bassi S, Jadhav K, Chand P, Biswas M, Biswas MM, Rawal T, Kaur N, Pimple S, Bhagabaty SM (2026). Codevelopment, mplementation, and Evaluation of an AI-powered Conversational Interface for Tobacco Cessation: Protocol for a Single-Group Pre-Post Study. JMIR Research Protocols. 15:e82264.
4. Mojidra R, Kumari S, Gardi N, Thomas D, Bagal B, Khattry N, Gokarn A, Punatar S, Govekar R (2026). Functional substitution of imatinib-inactivated canonical oncoprotein BCR::ABL1 by overexpressed PLAG1 results in BCR::ABL1-independent resistance in blast phase of chronic myeloid leukemia. Leukemia Research.
5. Nair S, Inchanalkar M, Chavdaa R, Joshi A, Patil V, Noronha V, Prabhash K, Mahajan A, Sable N, Janu A, Rane S, Patil A, Sinha S, V.V. Sameema, Sonawane K, Nair D, Agarwal JP, Laskar S, Gupta T, D’Cruz A, Chaukar D, Pai P, Mahimkar MB, Chaturvedi P (2026). Effect of erlotinib and celecoxib as short-course neoadjuvant therapy in operable oral cavity squamous cell carcinoma: a randomized controlled window-of-opportunity trial. Oral Oncology. 182:108156.
|
|
|
|
|
|
|
Video of the Week
|
|
| Decoding HER2 Mutations and Overexpression in NSCLC: HER2 Biomarker Testing in Clinical Practice |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2018, FDA approved larotrectinib, the first drug that targets tumors with NTRK gene fusions.
|
|
|
|
Cancer News
|
| |
|
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer.
|
|
Oncology Nursing News , 08/10/2026
|
|
The decision is based on the phase 3 ATOMIC trial (Alliance A021502; NCT02912559), in which adding the PD-L1 inhibitor to modified FOLFOX6 (mFOLFOX6) reduced the risk of disease recurrence or death by 50% compared with mFOLFOX6 alone (HR, 0.50; 95% CI, 0.35-0.73)…
|
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
